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Summary Two monoclonal murine antibodies have been raised against a delipidated extract of human
cream. These antibodies were detected by immunohistological screening of hybridoma culture supernatants on
sections of human breast tissue. One of those antibodies (E29) was subsequently screened against a range of
normal and neoplastic human tissues and shown to react with a wide variety of human epithelia and with
mesothelial cells. Antibody E29 was unreactive with other cell types, with the exception of occasional plasma
cells. Antibody E29 is suitable for use on paraffin embedded tissue and represents a valuable reagent for the
identification of tumours of epithelial origin.
In 1977 Ceriani et al. described the production of a
polyclonal antiserum against defatted human
cream, and its immunocytochemical reactivity with
mammary epithelial cells. Subsequently a rabbit
antiserum was raised against this antigen
(Heyderman et al., 1979) and was shown to react
with both normal and neoplastic mammary
epithelium in histological sections. It was noted that
reactivity with this antiserum was most marked on
the luminal aspect of mammary epithelial cells. The
antiserum also reacted with many different normal
glandular epithelia and with adenocarcinomas from
a wide variety of sites including stomach, prostate,
uterus, ovary, lung, pleura and thyroid.
The antigen detected by this antiserum was
designated 'epithelial membrane antigen' (EMA) by
Heyderman et al. (1979) and subsequent studies
proved its value in the detection of breast
carcinoma metastases in histological sections of
liver, lymph nodes and bone marrow (Sloane et al.,
1980; Sloane & Ormerod, 1981) and in marrow
smears (Dearnaley et al., 1981). Anti-EMA
antiserum was also shown to be useful for
differentiating anaplastic carcinoma from malignant
lymphomas and for the recognition of spindle cell
epithelial malignancies (Sloane et al., 1983; Sloane
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& Ormerod, 1981). More recently it has been
reported that the antiserum may be used to detect
neoplastic cells in serous effusions (To et al., 1981,
1982) and also in bone marrow smears in which
they cannot be identified by routine haematological
examination (Dearnaley et al., 1983; Redding et al.,
1983).
In addition to these studies of direct relevance to
pathological diagnosis, the distribution of EMA has
been documented in fetal and adult tissues and its
expression on disordered squamous epithelium
reported (Sloane et al., 1982).
Epithelial membrane antigen has recently been
purified from human milk (Ormerod et al., 1983)
and shown to be markedly heterogeneous in nature,
covering a wide range of mol.wts. This suggests
that polyclonal antisera raised against the antigen
will contain antibodies directed against multiple
different determinants on the immunising material.
This fact, together with the difficulty inherent in
obtaining large amounts of polyclonal anti-EMA
antisera of reproducible quality, has prompted us to
raise monoclonal antibodies ofthis specificity. In the
present paper two such monoclonal antibodies are
described, together with details of their reactions
against the antigen used for immunisation, as
analysed by immunoblotting. One of these anti-
bodies has been extensively tested against normal
and neoplastic human tissues and shown to be a
valuable reagent for the detection of tumour
metastases and the diagnosis of anaplastic
carcinoma.
A comparison of its reactions with those of
polyclonal anti-EMA antibodies and another
monoclonal anti-EMA antibody is presented in an
accompanying paper (Heyderman et al., 1985).
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Materials and methods
Preparation ofantigen
Epithelial membrane antigen was prepared from
human milk as described elsewhere (Heyderman et
al., 1985).
Antibodies and immunohistological reagents
Rabbit anti-mouse Ig and peroxidase conjugated
antibodies against mouse Ig and rabbit Ig were
obtained from Dakopatts a/s. Complexes of
alkaline phosphatase and monoclonal anti-alkaline
phosphatase (APAAP complexes) were prepared as
described previously (Cordell et al., 1984).
Production ofmonoclonal antibody
Balb/c mice were immunised with 50 ug of EMA
antigen emulsified in Freund's complete adjuvant
on 4 occasions at 10 day intervals. One of the mice
was then given an i.v. injection of 100 pg of antigen
and sacrificed 3 days later. The spleen was removed
aseptically, a cell suspension prepared and fusion
with NSI myeloma cells performed as described
previously (Mason et al., 1983). Following 8 days
culture, supernatants were removed and tested for
activity by immunoperoxidase staining on cryostat
sections of a ductal carcinoma of breast.
Immunoenzymatic labelling techniques
Immunoperoxidase staining Staining was per-
formed by a two- or three-stage procedure as
described previously (Gatter et al., 1984a). In brief,
acetone fixed cryostat sections or de-waxed paraffin
sections were incubated in sequence with mono-
clonal antibody and with peroxidase-conjugated
rabbit anti-mouse Ig. In the two-stage method the
peroxidase reaction was then revealed by incubation
with diaminzobenzidine/H202 substrate. In the
three-stage technique an additional incubation with
peroxidase-conjugated swine anti-rabbit Ig was
performed prior to development of the peroxidase
reaction.
Immuno-alkaline phosphatase labelling This was
performed as described previously using the un-
labelled antibody APAAP technique (Cordell et al.,
1984) or by a two-stage indirect immuno-alkaline
phosphatase procedure. In the latter technique in-
cubation with monoclonal antibody was followed
by alkaline phosphatase-conjugated rabbit anti-
mouse Ig (kindly provided by Dr K.J. Pluzek). In
both procedures the enzyme label was revealed by
incubation with a substrate containing naphthol
AS-MX and either Fast Red or hexazotised New
Fuchsin (Cordell et al., 1984).
Tissues and cell samples
Samples of fresh and paraffin embedded tissue were
obtained from the Histopathology Department of
the John Radcliffe Hospital. Cytological samples
were kindly provided by Dr A.I. Spriggs of the
Clinical Cytology Laboratory, Churchill Hospital.
Immunoblotting
The preparation of milk fat membrane antigen used
for immunisation was electrophoresed in a vertical
5% polyacrylamide slab gel (Laemmli, 1970), 20pg
of antigen being applied to each track. The
separated constituents of the antigen were then
transferred electrophoretically to nitrocellulose
membrane in a Bio-Rad Trans-Blot cell, according
to the method of Towbin et al. (1979). The
membrane was then incubated in turn with
monoclonal antibody, unlabelled sheep anti-mouse
Ig and APAAP complexes, as described previously
(Cordell et al., 1984). The alkaline phosphatase
reaction was then developed using naphthol AS-
MX phosphate and Fast Red as substrate (Cordell
et al., 1984).
Results
Production ofmonoclonal antibodies
At the time of initial screening, 8 days following
cell fusion, growth was observed in 135 tissue
culture wells. Screening by immunoperoxidase
labelling on tissue sections of breast carcinoma
revealed positive labelling with five supernatants.
Two of these (from cultures designated E29 and
E103) were selected for further study. The reactions
of these antibodies were maintained during
subsequent cloning and culture of the hybridoma
cells.
Analysis ofantibodies by immunoblotting
Antibidies E29 and E103 were tested by the im-
munoblotting procedure against the immunising
antigen following its electrophoresis in SDS poly-
acrylamide gel and transfer to nitrocellulose paper
(Figure 1). Both antibodies reacted with material
covering a wide range of mol.wts (265-400kD for
E29, 280-400kD for E103).
Immunocytochemical reactions ofantibody E29
Antibody E29 reacted with approximately equal
intensity with both cryostat and paraffin embedded
tissue sections.
Normal tissues: Details of the labelling reactions
observed are tabulated in Table I. Epithelial cells in
a wide variety of tissues and mesothelial cells wereMONOCLONAL ANTIBODIES TO EMA 349
Table I Immunohistological labelling of normal
E29.
Tissue
Skin:
Epidermis
Sweat ducts
Sebaceous glands
Gastro-intestinal tract:
Epithelium (tongue, oesophagus,
gastric parietal cells, small
intestine, colon, rectum)
Breast ducts
Acini
Ducts
Pancreas:
Exocrine
Endocrine
Bladder epithelium
Kidney
Glomeruli
Proximal tubules
Distal tubules
Cervix
Endometrium
Central nervous system
Peripheral nervous system
Lymphoid tissue
Respiratory epithelium
(bronchi, alveoli)
Thyroid
Connective tissue
Liver:
Bile ducts
Hepatocytes
tissue with monoclonal antibody
Result
+
+
+
+
+
+
+
+
- (except for occasional plasma cells)
+
strongly stained (Figure 2-6). In addition, in a
number of samples of different tissues, it was noted
that the antibody stained occasional scattered
plasma cells. No reactions were observed with other
cell or tissue types.
Neoplastic tissues: The reactions of antibody E29
against neoplastic tumour cells are summarised in
Tables II & III. The antibody reacted with a wide
variety of neoplastic epithelia, and also with neo-
plastic mesothelial cells (Figure 7). In addition the
antibody was shown to react strongly with neo-
plastic plasma cells from a case of multiple
myeloma.
Discussion
It is evident from the results reported above that
the immunocytochemical reactions of antibody E29
are closely similar to those obtained with the poly-
clonal antiserum anti-EMA (Heyderman et al.,
1979; Sloane & Ormerod, 1981; Sloane et al., 1982).
In particular it is of interest that the antibody
shows a broad spectrum of reactivity against
human epithelial cells, despite its having been raised
against an extract of human milk. In keeping with
previous studies of polyclonal anti-EMA the
monoclonal reagent was unreactive with normal350 J. CORDELL et al.
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Table II Reactions of Monoclonal Antibody E29 on cells
in serous effusions.
Cell type Reactions
Benign mesothelial cells -(+)
Mesothelioma +
Carcinoma:
Lung - adenocarcinoma +
- undifferentiated +(-)
- oat cell +
- squamous +
Breast +
Ovary +
Colon +
-(+): All but occasional cases negative. Staining of
benign mesothelial cells was seen in only 13/160 samples
tested (8%), and in many of these smears only one or two
positive mesothelial cells were seen (usually weakly
stained). +(-): All but occasional cases positive.
Table III Immunohistological labelling
tissues by antibody E29.
of neoplastic
95,000 _n
Figure 1 Immunoblotting of milk fat preparation
with antibody E29. Labelling is seen diffusely in the
region immediately below the origin (at the top of the
nitrocellulose filter). Note that the intensity of labelling
is relatively weak and that it is localised principally
towards the margins of the electrophoretic track. A
similar pattern has been observed by Burchell et al.
(1983) with antibody HMFG2 (which shows very
similar reactions on tissue sections to antibody E29).
squamous epithelium but stained this tissue strongly
when it had undergone neoplastic transformation.
The reaction of antibody E29 with plasma cells is
of interest. In view of the potential risk. of false
diagnosis when staining anaplastic tumours, this
phenomenon has been investigated in a large
number of lymphoid neoplasms (Delsol et al., 1984;
Delsol, personal communication). It appears to be
common in plasma cell neoplasms, but is also
encountered occasionally among other types of
lymphoma, particularly among polymorphic large
cell lymphomas. However, it should be emphasised
Tumour type Result
Skin:
Basal cell carcinomas
Squamous cell carcinoma +
Melanoma
Gastro-intestinal:
Squamous carcinoma of tongue and
oesophagus +
Adenocarcinoma of stomach and colon +
Adenocarcinoma of breast +
Adenocarcinoma ofpancreas +
Transitional carcinoma of bladder +
Adenocarcinoma of kidney +
Squamous carcinoma ofcervix +
Adenocarcinoma of endometrium +
Tumours ofcentral and peripheral nervous
system
Lymphoproliferative tumours -/(+)a
Lung tumours:
Squamous cell carcinoma +
Adenocarcinoma +
Small cell carcinoma +
Follicular carcinoma of thyroid +
Papillary carcinoma of thyroid +
Connective tissue tumours
aOccasional lymphoid neoplasms reacted with antibody
E29 - see Delsol et al., 1984.MONOCLONAL ANTIBODIES TO EMA
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3a 3b
Figure 2 APAAP staining of normal gastric mucosa with antibody E29, showing strong labelling of gastric
parietal cells. In the higher power view (b) the intracanalicular localisation of the antigen is seen (see arrowed
cell).
Figure 3 APAAP staining of pancreas with antibody E29 shows strong labelling of exocrine glandular
elements but no reactivity of islets of Langerhans (IL). The higher power view (b) shows that labelling is
principally confined to the luminal aspect of the glandular cells.
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Figure 4 APAAP staining of kidney with antibody E29 shows strong labelling of distal tubules but no
reactivity ofproximal tubules or gomeruli.
Figure 5 APAAP staining of prostate with antibody E29. A strongly labelled glandular structure is seen,
with labelling principally on the luminal aspect of the cells. The intensity of the labelling varies markedly in
the prostate, some glandular elements showing no reactivity with antibody E29.
Figure 6 APAAP staining of normal mesothelium with antibody E29 shows strong staining of the cell
surface.
Figure 7 APAAP staining of mesothelioma cells in a pleural effusion smear with antibody E29. This staining
was performed on a smear which had been previously stained conventionally with May-Grunwald Giemsa,
and mounted for microscopy. In order to demonstrate EMA the coverslip was removed with xylol, and the
slide then transferred via alcohol to buffer, before applying antibody E29 and the reagents for APAAP
immuno-alkaline phosphatase labelling.
.40...
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that overall such cases are rare, and they are
usually clearly identifiable on purely morphological
grounds as being lymphoid in nature. This is
reflected in the fact that in a recent study of 120
tumour biopsies which required immunohistological
analysis to establish their cellular origin, reactivity
of lymphomas with antibody E29 was only rarely
seen, and did not pose any major practical obstacle
to diagnosis (Gatter et al., 1985). It may be noted,
however, in this context that the risk of
misdiagnosis in such cases can be further reduced
by the inclusion of an anti-cytokeratin in the
monoclonal antibody panel.
The antibodies described in the present paper
show similarities to the two monoclonal antibodies
against defatted preparations of human cream
(designated HMFG-1 and HMFG-2) reported by
Taylor-Papadimitriou et al. (1983) and by Arklie et
al. (1981), since they react with antigenic material
in human milk which is of high mol. wt (Burchell
et al., 1983) and give similar immunocytochemical
labelling reactions (Gatter et al., 1982). However it
should be noted that differences can be detected
between antibodies HMFG1 and HMFG2, when
their reactivity patterns are assessed by a variety of
techniques (immunoblotting, immunohistology,
binding to cell lines and lectin blocking - Burchell
et al., 1983, Taylor-Papadimitriou et al., 1985).
Antibody E29 may not be identical in specificity to
either of these reagents, and indeed the direct
comparison of immunohistological reactions
reported in the accompanying paper indicate that
antibody E29 gives cleaner labelling of human
tissues than antibody HMFG2.
Foster et al. (1982) have reported the production
of monoclonal antibodies (designated M8 and M18)
against human milk fat globules which also react
with high mol. wtmolecules ofheterogenous size, and
show close similarities in their immunohistochemical
reactions to antibody E29. More recently Ellis et al.
(1984) have reported a monoclonal antibody
(NCRC-l1) which was raised against human breast
carcinoma cells and which gives immunohistological
labelling reactions very similar to those of E29.
Antibody NCRC-1 1 was also able to partially
inhibit binding of one of the anti-EMA antibodies
reported by Foster et al. (LICR-LON/M8).
It is evident from the results reported in this
paper that antibody E29 is of considerable practical
diagnostic value because of the clarity with which it
labels cells of epithelial origin in routine paraffin
embedded tissue and in air dried routine cytological
smears. It reacts with all mammary carcinomas
against which it has been tested, and has been
shown to be capable of detecting micrometastases
of this tumour in 15% of axillary lymph nodes
from breast carcinoma patients in whom tumour is
undetectable on routine histological examination
(Wells et al., 1984). Furthermore antibody E29 may
be used to detect metastatic carcinoma cells in
routinely prepared smears of bone marrow aspirates
(Ghosh et al., 1985). The antibody is of particular
value when used in conjunction with monoclonal
antibodies which react with leucocyte-associated
antigens, since this combination of antibodies
enables the majority of anaplastic tumours of
uncertain type to be reliably classified as either
lymphoma or carcinoma (Gatter et al., 1984a,b,
1985).
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